Similar articles

• Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Reply.

  Ory J, Ramasamy R. Ory J, et al. J Urol. 2022 Sep;208(3):567. doi: 10.1097/JU.0000000000002791. Epub 2022 Jun 1. J Urol. 2022. PMID: 35648647 No abstract available.
• Editorial Comment: Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy.

  Barros R. Barros R. Int Braz J Urol. 2023 Jan-Feb;49(1):150-151. doi: 10.1590/S1677-5538.IBJU.2023.01.04. Int Braz J Urol. 2023. PMID: 36512463 Free PMC article. No abstract available.
• Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.

  Ory J, Nackeeran S, Balaji NC, Hare JM, Ramasamy AR. Ory J, et al. J Urol. 2022 Jun;207(6):1295-1301. doi: 10.1097/JU.0000000000002437. Epub 2022 Jan 20. J Urol. 2022. PMID: 35050717
• Erythrocytosis Following Testosterone Therapy.

  Ohlander SJ, Varghese B, Pastuszak AW. Ohlander SJ, et al. Sex Med Rev. 2018 Jan;6(1):77-85. doi: 10.1016/j.sxmr.2017.04.001. Epub 2017 May 16. Sex Med Rev. 2018. PMID: 28526632 Free PMC article. Review.
• Risks of testosterone-replacement therapy and recommendations for monitoring.

  Rhoden EL, Morgentaler A. Rhoden EL, et al. N Engl J Med. 2004 Jan 29;350(5):482-92. doi: 10.1056/NEJMra022251. N Engl J Med. 2004. PMID: 14749457 Review. No abstract available.